© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to October
oral LPA1 GPCR receptor antagonist
Ph. II candidate for IPF (60 mg BID)
from addressing tox. of prior candidate
Journal of Medicinal Chemistry
Bristol Myers Squibb, Princeton, NJ
This month’s cover molecule, BMS-986278, is an LPA1 antagonist and oral (up to 125 mg BID) Ph. II clinical candidate for idiopathic pulmonary fibrosis (IPF) (NCT04308681). Reviewer and nominator Christian Kuttruff says: “While…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.